373 related articles for article (PubMed ID: 10619466)
1. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
Fisher A; Biggs CS; Eradiri O; Starr MS
Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466
[TBL] [Abstract][Full Text] [Related]
2. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
3. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
4. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
6. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
7. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.
Neff NH; Wemlinger TA; Hadjiconstantinou M
J Neural Transm (Vienna); 2000; 107(4):429-43. PubMed ID: 11215754
[TBL] [Abstract][Full Text] [Related]
8. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Ren LQ; Wienecke J; Hultborn H; Zhang M
J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
[TBL] [Abstract][Full Text] [Related]
9. Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Arai A; Kannari K; Shen H; Maeda T; Suda T; Matsunaga M
Brain Res; 2003 May; 972(1-2):229-34. PubMed ID: 12711097
[TBL] [Abstract][Full Text] [Related]
10. L-dopa facilitates the release of endogenous norepinephrine and dopamine via presynaptic beta 1- and beta 2-adrenoceptors under essentially complete inhibition of L-aromatic amino acid decarboxylase in rat hypothalamic slices.
Goshima Y; Nakamura S; Misu Y
Jpn J Pharmacol; 1990 May; 53(1):47-56. PubMed ID: 1972204
[TBL] [Abstract][Full Text] [Related]
11. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
Treseder SA; Jackson M; Jenner P
Br J Pharmacol; 2000 Apr; 129(7):1355-64. PubMed ID: 10742291
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain.
Fisher A; Starr MS
Brain Res; 2000 Jun; 868(2):268-74. PubMed ID: 10854579
[TBL] [Abstract][Full Text] [Related]
13. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
[TBL] [Abstract][Full Text] [Related]
14. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
15. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
GoĊembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
16. Alteration in L-DOPA evoked dopamine and DOPAC output under conditions of impaired vesicular dopamine storage.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1998; 105(10-12):1091-101. PubMed ID: 9928880
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats.
Biggs CS; Fowler LJ; Whitton PS; Starr MS
Eur J Pharmacol; 1996 Mar; 299(1-3):83-91. PubMed ID: 8901010
[TBL] [Abstract][Full Text] [Related]
18. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
Mura A; Jackson D; Manley MS; Young SJ; Groves PM
Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961
[TBL] [Abstract][Full Text] [Related]
19. Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
GoĊembiowska K; Dziubina A
Brain Res; 2004 Feb; 998(2):208-17. PubMed ID: 14751592
[TBL] [Abstract][Full Text] [Related]
20. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
